Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $64.86.

A number of brokerages recently issued reports on ARCT. Canaccord Genuity Group decreased their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, July 2nd.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $40.01, for a total value of $1,040,260.00. Following the completion of the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at $17,902,394.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Great Lakes Advisors LLC acquired a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at $6,531,000. ARK Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock valued at $64,564,000 after acquiring an additional 146,141 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Arcturus Therapeutics by 239.8% during the 3rd quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock valued at $4,400,000 after acquiring an additional 121,526 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Arcturus Therapeutics by 11.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after acquiring an additional 115,087 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter valued at $2,738,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Trading Up 4.2 %

NASDAQ:ARCT opened at $22.48 on Wednesday. The firm has a market capitalization of $605.39 million, a PE ratio of -5.75 and a beta of 2.64. The stock has a 50 day moving average of $29.54 and a 200-day moving average of $32.25. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.17. The company had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. As a group, analysts predict that Arcturus Therapeutics will post -4.39 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.